AVENUE THERAPEUTICS, INC. (ATXI) — Insider Trading

Key Insights

• The reporting person, Fortress Biotech, Inc., acquired an additional 111,209 shares of AVENUE THERAPEUTICS, INC. (ATXI) common stock as an annual dividend on its Class A Preferred Stock, indicating continued investment in the company.
• The transaction suggests Fortress Biotech maintains a significant 10% ownership stake in ATXI, with a total of 439,733 shares following the reported acquisition.
• The annual dividend payment and steady ownership position signal Fortress Biotech's ongoing confidence in ATXI's long-term prospects and strategic direction.